Research and Markets: PharmaPoint Report: Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2022
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dmrwcb/pharmapoint) has announced the addition of the "PharmaPoint: Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2022" report to their offering.
“PharmaPoint: Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2022”
Growth within that market will stem from the positive uptake of three therapies: cyclosporine, systemic antihistamines and the Japanese-manufactured topical calcineurin inhibitor, Astellas/Maruho's Protopic. Collectively, these three therapies will contribute $361.9m sales to the 2022.
Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.
By the mid-to-late term of Our 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.
Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.
- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Atopic Dermatitis market.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/dmrwcb/pharmapoint